Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration
Journal of Clinical Oncology · 20.11.2026 · 44 (33) · 3281-3281
DOI: 10.1200/jco-26-00911 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.11.2026. Verfasst von Gai Liang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Gai Liang, MD, Qu Zhang, MD; and Mengting Yuan, MM, Department of Radiation Oncology, Hubei Cancer Hospital, TongJi Medical College, Huazhong Univers…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Gai Liang, MD, Qu Zhang, MD; and Mengting Yuan, MM, Department of Radiation Oncology, Hubei Cancer Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Qu Zhang, Mengting Yuan
Zitieren
APA
Liang, G., Zhang, Q., & Yuan, M. (2026). Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration. Journal of Clinical Oncology, 44(33), 3281-3281. https://doi.org/10.1200/jco-26-00911
Vancouver
Liang G, Zhang Q, Yuan M. Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration. Journal of Clinical Oncology. 2026;44(33):3281-3281. doi:10.1200/jco-26-00911
BibTeX
@article{Liang2026,
author = {Liang, Gai and Zhang, Qu and Yuan, Mengting},
title = {Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {33},
pages = {3281--3281},
doi = {10.1200/jco-26-00911}
}
EUVIMED